Cti Biopharma Stock Price, News & Analysis

CTI BioPharma Corp. (NASDAQ: CTIC) announced equity inducement awards for two new employees, totaling 90,000 options to purchase shares. Approved on May 12, 2021, these awards comply with Nasdaq Listing Rule 5635(c)(4). The options will be granted at the employees' respective Grant Dates, with an exercise price equal to the closing stock price of CTIC on that date. Vesting occurs annually, with a total term of ten years. CTI focuses on developing targeted therapies for blood-related cancers, notably pacritinib, currently evaluated for myelofibrosis and severe COVID-19 treatment.

CTI BioPharma Corp. (NASDAQ: CTIC) will announce its first quarter 2021 financial results on June 1, 2021, after U.S. market close. A conference call is scheduled for 4:30 p.m. ET to discuss the results and provide a corporate update. Interested participants can join the call by dialing (877) 735-2860 domestically or (602) 563-8791 internationally, using conference ID 9343326. Additionally, a live audio webcast will be available on CTI's website, with a replay accessible for 30 days. CTI focuses on developing targeted therapies for blood-related cancers, primarily evaluating pacritinib.

CTI BioPharma Corp. (NASDAQ: CTIC) announced that its Board of Directors has granted equity inducement awards to two new employees, totaling 80,000 options to purchase common stock. These awards were approved on April 21, 2021, in compliance with Nasdaq Listing Rule 5635(c)(4). The options will have an exercise price equal to the stock's closing price on each Grant Date and will vest over four years, contingent on continued employment. CTI BioPharma is focused on developing therapies for blood-related cancers, particularly myelofibrosis and severe COVID-19.

CTI BioPharma Corp. (NASDAQ: CTIC) will present a corporate overview at the 20th Annual Needham Virtual Healthcare Conference on April 14, 2021, at 3:00 p.m. EST. The event will be conducted virtually and the presentation will be available for live webcast and replay on the company's website. CTI BioPharma focuses on developing targeted therapies for blood-related cancers, with a key focus on pacritinib, their candidate in late-stage development for myelofibrosis and severe COVID-19. The company is headquartered in Seattle, Washington.

CTI BioPharma Corp. (NASDAQ: CTIC) announced the granting of equity inducement awards to three new employees, totaling options to purchase 107,500 shares of common stock. Approved by the Compensation Committee on April 1, 2021, these awards are in accordance with Nasdaq Listing Rule 5635(c)(4). Each equity award will have an exercise price equal to the stock's closing price on the Grant Date and will vest over four years. CTI BioPharma focuses on developing targeted therapies for blood-related cancers, particularly myelofibrosis and severe COVID-19.

SEATTLE, March 31, 2021 /PRNewswire/ -- CTI BioPharma Corp. (CTIC) announced the pricing of its public offering of 14,260,800 common shares at $2.50 each, along with 600 shares of Series X¹ Preferred Stock priced at $25,000 each. The underwriters have a 30-day option for an additional 2,139,120 shares. Gross proceeds are estimated at $50.7 million, intended for commercialization of pacritinib, working capital, and corporate needs. The offering is set to close on April 6, 2021, pending customary conditions.

CTI BioPharma Corp. (Nasdaq: CTIC) announced a proposed underwritten public offering of common stock and Series X¹ preferred stock. All offered securities will be sold by CTI, with the exact size and terms dependent on market conditions. The proceeds are designated for commercialization activities related to pacritinib, general working capital, and corporate purposes. Stifel and JMP Securities are joint book-running managers for the offering. The offering is subject to SEC regulations, and there is no guarantee of completion.

CTI BioPharma Corp. (Nasdaq: CTIC) has completed a rolling New Drug Application (NDA) submission to the FDA for pacritinib, targeting myelofibrosis patients with severe thrombocytopenia. The submission is based on data from Phase 3 trials PERSIST-1 and PERSIST-2, as well as Phase 2 trial PAC203. With plans for a commercial launch by the end of 2021, CTI is also executing pre-commercialization activities and has formed a leadership team. The urgent need for effective treatment options for this patient group highlights the significance of this initiative.

CTI BioPharma Corp. (Nasdaq: CTIC) announced positive findings from a Phase 1 trial published in Clinical Cancer Research, showcasing the safety and preliminary efficacy of pacritinib, a JAK2 inhibitor. The study evaluated pacritinib combined with sirolimus and low-dose tacrolimus for preventing acute graft-versus-host disease (GVHD) post-allogeneic hematopoietic cell transplantation. Key results indicate a favorable safety profile, with only one participant experiencing Grade 2-4 acute GVHD. The ongoing Phase 2 trial aims to further assess pacritinib's therapeutic effects for GVHD prevention.